Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deleted in primary ciliary dyskinesia homolog (DPCD) is a protein crucial for the formation and maintenance of cilia, the hair-like organelles present on certain cell types. The absence or mutation of DPCD results in primary ciliary dyskinesia, a rare genetic disorder characterized by defective ciliated cell function, leading to mucociliary clearance issues and chronic respiratory disease. DPCD interacts with RUVBL1 and RUVBL2 (AAA+ ATPases), suggesting a role in assembly or regulation of macromolecular complexes essential for cilia biogenesis. DPCD is considered a structural or cofactor protein, not a conventional drug target, and no drugs, mechanisms, or biomarker uses are associated with it[1][4][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deleted in primary ciliary dyskinesia homolog (DPCD).